Study study type PathologyT1T0Patientssample sizesROB Results

mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population

versus Standard of Care (SoC)
ipatasertib plus paclitaxel
LOTUS, 2017
  NCT02162719
RCTmBC - TNBC - L1 - all populationipatasertib plus paclitaxelplacebo plus paclitaxelWomen with locally advanced or metastatic TNBC not amenable to curative resection. Previous systemic therapy for locally advanced or metastatic disease was not permitted. Previous (neo)adjuvant treatment completed at least 6 months before the first dose was allowed62 / 62NA
suggested
  • suggested 40 % decrease in progression or deaths (PFS) (PE)